The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...
Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...
Administration of the novel Flt3 inhibitor, crenolanib, in conjunction with intensive chemotherapy, results in high response rates with acceptable toxicity supporting its current evaluation in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results